Bryn Mawr Hospital first site in world to enroll patient and complete protocol in landmark JANUS trial for sleep apnea

remede System with tablet

Bryn Mawr Hospital, part of Main Line Health’s Lankenau Heart Institute, on August 18, 2020 became the first site in the world to successfully enroll a patient and complete the protocol in JANUS, a landmark clinical trial for sleep apnea. The trial seeks to explore whether transvenous stimulation can improve airway physiology. In this first patient, Sheetal Chandhok, MD, the investigator and implanting physician, was able to demonstrate feasibility in this novel approach for managing sleep apnea.  

Sleep apnea---when prolonged pauses in breathing occur during sleep---is a serious health issue for many Americans. An estimated 22 million Americans suffer from some degree of sleep apnea, a condition that causes breathing to abruptly stop and restart during sleep. In addition to poor sleep quality, sleep apnea can lead to high blood pressure, heart failure, atrial fibrillation, stroke and other health issues.

The primary objective of the JANUS trial, sponsored by Respicardia, is to assess acute changes in respiration and airway physiology during sleep. The trial is being conducted in patients with central sleep apnea who are undergoing a Remedé system implant, which uses transvenous stimulation to reduce the periods of the breathing pauses. The JANUS trial is conducted during the implantation of commercially available device called the Remede® System, a diaphragm pacemaker that works to stimulate breathing in the same way that the brain would. The Remede® System was first implanted at Bryn Mawr Hospital by Dr. Sheetal Chandhok, a cardiac electrophysiologist, in January 2019. 

“Central sleep apnea occurs when the brain temporarily stops sending signals to the muscles that control our breathing. When that happens, this pacemaker (the Remede® System) sends a signal to the phrenic (diaphragm) nerve to trigger breathing. This prevents the risk of interrupted breathing at night, and currently is the only approved treatment for central sleep apnea,” explains Sheetal Chandhok, MD, an electrophysiologist with Bryn Mawr Medical Specialists Association and a member of Lankenau Heart Institute. “In the JANUS trial we hope to show that an alternative transvenous lead location can affect respiration and airway physiology during a commercial Remedē® System implant procedure”.

Dr. Chandhok is one of three primary investigators for the JANUS trial and was the first clinician in the world to enroll a subject and complete the objective for the trial. “The potential success of JANUS trial may have far-reaching implications for a broader set of sleep apnea patients for whom there are only limited treatments,” he said. 

The JANUS trial is currently enrolling subjects who are undergoing transvenous phrenic nerve stimulation for moderate to severe central sleep apnea using the Remedē® System. Participants must be over 18. To learn more about this trial or to enroll, visit clinicaltrials.gov.

 

About Bryn Mawr Hospital

Founded in 1893, Bryn Mawr Hospital is recognized for its exceptional patient care. The hospital and its outpatient locations, located in the Philadelphia metro area, offer a wide range of services, including behavioral health, cancer care, gastroenterology, orthopaedics, neurointervention and neurosurgery, cardiovascular, maternity, bariatric surgery, urology, plastic and reconstructive surgery.

Main Line Health and Children's Hospital of Philadelphia (CHOP) have an affiliation to provide pediatric care to our community, including 24/7 coverage of the pediatric emergency department, pediatric inpatient unit and level III NICU. Main Line Health is one of the few community health systems in the region offering state-of-the-art neurointervention care. Through our collaboration with the Jefferson Hospital for Neuroscience, the hospital is a Thrombectomy-Capable Stroke Center.

Bryn Mawr Hospital offers an inpatient psychiatric program. The program cares for adults struggling with mood, anxiety and thought disorders, co-occurring substance abuse or addiction, and other psychiatric conditions.

About Lankenau Heart Institute

Lankenau Heart Institute is Main Line Health's premier comprehensive cardiovascular program, bringing together the collective expertise of cardiologists, cardiovascular surgeons and advanced practice providers across all four of the System's acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital. Through a coordinated approach, Lankenau Heart Institute offers a full continuum of high-quality cardiovascular care, from prevention and diagnostics to advanced treatments and rehabilitation, delivered with a commitment to excellence in outcomes and patient experience.

A leader in innovation, Lankenau Heart Institute is at the forefront of minimally invasive and transcatheter procedures for coronary revascularization, valve repair and replacement, complex aortic surgery and the treatment of advanced heart failure and arrhythmias. Its pioneering work in robotic-assisted and beating-heart techniques and minimally invasive valve repair continue to shape the future of cardiovascular care. With a robust and growing presence in national clinical trials, its physicians regularly participate in groundbreaking research focused on the latest therapies, technologies and procedures, focusing primarily on less invasive approaches.

About Main Line Health

Founded in 1985, Main Line Health® is a not-for-profit health system serving the Philadelphia region and beyond. Main Line Health consists of five hospitals, six health centers and over 150 medical practice locations. The System has more than 14,000 employees and over 2,100 employed and independent physicians and advanced practice providers.

At its core are four of the region's most respected acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital — as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehab Hospital. Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, providing skilled home healthcare, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; and Lankenau Institute for Medical Research, a biomedical research organization.

Main Line Health's medical staff benefits from a collaborative relationship including independent physicians, community healthcare professionals and hospital-based experts from Main Line HealthCare, the employed multi-specialty physician network of Main Line Health.

Main Line Health collaborates with top experts to deliver exceptional specialty care. Through our affiliation with the Children's Hospital of Philadelphia, doctors and advanced practice providers care for pediatric patients at select Main Line Health locations, including the neonatal intensive care units at Main Line Health's four acute care hospitals, as well as Bryn Mawr Hospital's Inpatient Pediatric Unit and Emergency Department. Jefferson Health neurosurgeons and neurointerventionalists provide 24/7 specialized care, including neurointervention and lifesaving stroke care, and trauma surgeons provide critical care to our patients. Through our affiliation with Sheppard Pratt — a nonprofit provider of mental health services, substance use, developmental disability and other comprehensive behavioral health support — patients receive compassionate care in a welcoming environment.

For more information, visit mainlinehealth.org and connect with us on social media:

LinkedIn: www.linkedin.com/company/main-line-health
Facebook: www.facebook.com/mainlinehealth
X (formerly known as Twitter): www.twitter.com/mainlinehealth
Instagram: www.instagram.com/mainlinehealth

Contact

Phil Ellingsworth, Jr.
Director, Communications
Office: 484.580.1182
EllingsworthPh@mlhs.org